Maxillary devices and Mandibular devices each have a first housing connectable to a tooth of a user or connectable or integral with a teeth covering, wherein the housing encloses an on-board circuit board and a power source. The first housing of the maxillary devices has a tooth connecting portion, a palate housing portion and/or a buccal housing portion. The first housing of the mandibular devices has a tooth connecting portion and a sublingual portion. Each of the palate housing portion and the buccal housing portion enclose a stimulator having an electrode electrically connected to the on-board circuit board and the power source, and can enclose a sensor and/or a medicament dispenser. The sublingual portion encloses a sensor and a medicament dispenser each of which are in electrical communication with the microprocessor of the on-board circuit board.

An inhaler includes a mouth-piece cover, a pressure sensor, a first indicator and a second indicator. The first indicator may be configured to indicate based on a state of the cover, and the second indicator may be configured to indicate based on an output of the pressure sensor. For example, when the mouthpiece cover opens, the first indicator may illuminate and a dose of medication may be transferred from a reservoir to a dosing cup. The second indicator may illuminate if an amount of inhaled medication reaches a predetermined threshold for successful inhalation.

A tidal dry powder inhaler comprising: a miniature pressure sensor, a sensor port of said sensor being pneumatically coupled to a flow channel through which a user can inhale; a processor configured to process data received from a sensing element of the sensor to make a determination that inhalation of a spontaneous breath through said flow channel is in progress; a controller configured to, responsive to said determination, issue a start dosing signal; and a dosing mechanism configured to release dry powder medicament into the flow channel during inhalation of said spontaneous breath in response to receiving said signal.

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Various methods and devices of treating infectious diseases are described. In one example embodiment, a method of treating an infectious disease in an individual in need thereof is provided, including administering a therapeutic agent to the individual and electroporating a tissue of the individual, wherein the therapeutic agent is inhalable.

A device and associated method for the dispensation of mists for therapeutic use, comprising: a dispensing member (2) for dispensing an air flow (3) within which micronized particles of a liquid or solid therapeutic substance are dispersed; a chamber (11) having at least one inlet (12) for said air flow (3) generated by the dispensing member (2) and at least one outlet (13) for said air flow (3) present inside the chamber (11) itself; and a communication conduit (10) interposed between said dispensing member (2) and said chamber (11) in order to introduce the air flow (3) into the chamber (11) itself; said chamber (11) being switchable between an operative condition of maximum volume in which it internally defines a space (20) for containing at least one user, and a non-operative condition of minimum volume suitable for transport and/or storage.

Some embodiments are directed to a compliance monitor for monitoring patient usage of a dry powder medicament delivery device, including a store of medicament housed within a main body portion, and a base portion which is rotatable with respect to the main body portion. The medicament delivery device also includes a medicament dispensing means for dispensing a dose of medicament into an inhalation chamber, a mouthpiece through which the dose of medicament may be inhaled by a user, and a replaceable cap. The compliance monitor includes a first portion for receiving and/or retaining the base portion of the medicament delivery device, and a second portion for releasably securing the medicament delivery device to the first portion. The arrangement and construction is such that the fitting of the second portion of the compliance monitor to the first portion of the compliance monitor does not include a screw fit.

Provided are active agent delivery devices configured to deliver an active agent formulation into or through a mucosal layer in a subject. The active agent delivery devices include a power reservoir configured to eject the active agent formulation at a pressure sufficient to deliver the active agent formulation into or through a mucosal layer in a subject. Methods of using the subject active agent delivery devices are also provided.

A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.

A powder aerosolization apparatus comprises a housing comprising an outlet adapted to be inserted into a user's mouth and one or more bypass air openings. A receptacle support within the housing supports a receptacle containing a powder pharmaceutical formulation. A puncturing mechanism within the housing creates in the receptacle one or more inlet openings and one or more powder outflow openings, wherein the powder outflow openings have a total area of from 0.2 mm.sup.2 to 4.0 mm.sup.2. Upon a user's inhalation through the outlet, air flows through the one or more bypass air openings and through the receptacle to aerosolize the powder pharmaceutical formulation in the receptacle. In one version, the relative flow parameters between the flow through the one or more bypass openings and the one or more powder outflow openings are selected so that flow of aerosolized pharmaceutical formulation does not occur until a predetermined inhalation flow rate is achieved.